Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Nocturia, a common and troubling condition among older adults in Taiwan, often disrupts sleep quality and affects mental health while increasing the risk of falls. This research evaluates a new community-based approach that combines digital health technology and behavioral therapy to manage nocturia in people aged 55 and older who experience two or more nighttime voids. The goal is to reduce nocturnal voiding frequency, improve quality of life, and explore reducing medication reliance. Participants are divided into two groups. The intervention group uses a non-contact home uroflowmetry device and a voiding diary to track urinary patterns, receiving real-time feedback. They also get personalized lifestyle advice such as fluid restriction and leg elevation, alongside psychiatric screening for sleep and mood disorders. The control group receives general health education and follow-up without these devices or personalized interventions. Throughout the study, participants record their voiding habits for 2-3 consecutive days monthly over six months. Researchers assess nocturnal void frequency, sleep quality, mental health, anxiety, quality of life, and fall or emergency events at the start, three months, and six months after randomization. This comprehensive monitoring helps evaluate the effectiveness of the community-based management model integrating digital tools and behavioral support.
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are studying cervical cancer screening participation by comparing a traditional Pap test with a modified version that includes a non-painful step at the end of the procedure. This multicenter randomized controlled trial aims to expand on previous findings about pain reduction during Pap smears and evaluate whether the modified test can increase participation rates. The study involves women aged 25 and older who have not yet undergone Pap tests, focusing on improving screening uptake through innovative, low-cost strategies. Participants are randomly assigned to receive either the traditional Pap test or the modified Pap test, where the speculum is gently held in place for 15 seconds after sample collection to reduce recalled pain. The Pap test procedure is standardized and performed by trained operators behind a privacy curtain. The trial includes recruitment from 2026 to 2029 with a target enrollment of 850 participants, and follow-up will continue through 2032. During the study, participants will undergo interviews to collect medical, lifestyle, and psychological data including anxiety and stress assessments. Anthropometric measurements and blood pressure will also be taken. Pain during and after the Pap test is carefully measured using numeric and visual scales immediately and up to three months later. The main outcome is the rate of cervical cancer screening participation within three years, with additional monitoring of pain intensity and screening uptake at one year. Statistical analyses will evaluate the effectiveness of the modified test in increasing screening rates while maintaining specimen quality.
Actively Recruiting
Researchers are studying somatic symptom disorder SSD, a psychiatric condition characterized by distressing physical symptoms and related psychological issues. This study aims to develop and test an integrative psychotherapy combining cognitive-behavioral therapy CBT and biofeedback therapy to assess its effects on treating SSD. The research uses a randomized controlled design with a waiting list control group to compare outcomes like patient health and health anxiety. Participants in the experimental group will receive eight sessions of CBT and biofeedback therapy over three months. The control group will initially be on a waiting list without intervention, with data collected during this observation period. Afterward, they will also receive the same psychotherapy as the experimental group. Biofeedback therapy involves monitoring biological signals related to stress and relaxation to help patients understand their connection to physical and mental responses. Throughout the study, participants will be assessed using questionnaires such as the Patient Health Questionnaire-15 and Health Anxiety Questionnaire, along with other psychological and biological measures like depression, anxiety, cognition about health, heart rate variability, and skin conductance. The primary outcomes will be measured at week 12 compared to baseline. The study is sponsored by National Taiwan University Hospital and includes adults aged 20 to 70 years with confirmed SSD.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effectiveness of two simulation training methods, In-situ Simulation ISS and Off-site Simulation OSS, using the A-C-L-S teamwork model to improve adult non-trauma cardiac arrest resuscitation teams. This study uses a two-group non-randomized pre-post design conducted at two different campuses of the National Taiwan University Hospital Yunlin Branch. The goal is to compare team performance and patient outcomes between teams trained in real clinical environments versus those trained in dedicated simulation centers. Participants in the ISS group receive high-fidelity simulation training in their actual emergency department, including a 20-minute briefing, 10-minute simulation exercise, and 30-minute debriefing focused on teamwork and non-technical skills. The OSS group undergoes similar training at a separate simulation center with the same timing and teamwork focus but outside the clinical setting. Both groups follow the A-C-L-S model for structuring team roles during adult non-trauma resuscitation. Throughout the one-year study period, team performances are assessed by blinded external experts using video recordings and the Team Emergency Assessment Measure TEAM scale to evaluate non-technical skills. Secondary outcomes include timing of resuscitation steps, quality of chest compressions, and patient return of spontaneous circulation rates. Data collection aims to support evidence-based education, improve resuscitation efficiency, and enhance institutional teaching and research capabilities.
Actively Recruiting
Researchers are studying adults with pulmonary hypertension associated with interstitial lung disease PH-ILD to evaluate the effects of a 24-week daily treatment using Treprostinil Palmitil Inhalation Powder TPIP compared to a placebo. This phase 3, randomized, double-blind, placebo-controlled study aims to assess how TPIP impacts exercise capacity in this group. Participants will receive either TPIP once daily, starting at 80 micrograms and increasing to a maximum tolerated dose of 1280 micrograms, or a placebo inhaled via a capsule-based dry powder inhaler. The treatment period lasts for 24 weeks, and both groups use the same type of inhalation device to maintain blinding. During the study, participants will undergo assessments including the 6-minute walk test to measure exercise capacity and blood tests to track heart-related biomarkers like NT-proBNP. Researchers will monitor clinical worsening events, adverse effects, and plasma drug levels throughout the 24-week treatment. The study is designed to provide detailed information about TPIPs impact on PH-ILD over this period.
Actively Recruiting
This research aims to compare pain control methods for patients with hip fractures in the emergency department. It evaluates ultrasound-guided femoral nerve blocks performed by emergency physicians against the usual use of pain medications like opioids or NSAIDs. The study focuses on how quickly pain relief is achieved, the amount of rescue pain medication needed, and patient satisfaction, while monitoring for adverse effects and complications. Participants receive either an ultrasound-guided femoral nerve block, where local anesthetic is injected around the femoral nerve using ultrasound, or traditional intravenous or intramuscular pain medications. The study uses a prospective before-and-after design, enrolling patients aged 20 and older who stay in the emergency department for at least two hours. Pain severity is assessed using a 0-10 numerical rating scale at 30-minute intervals. During the study, researchers measure pain relief within two hours after treatment, patient satisfaction, adverse effects, and complications related to nerve blocks up to one week after the procedure or hospital discharge. Pain scores are recorded every 30 minutes before and after pain management. The total participation time includes at least two hours in the emergency department with follow-up for complications after discharge.
Actively Recruiting
Researchers are evaluating the drug U101 to see if it can prevent recurrent urinary tract infections rUTIs in women aged 20 to under 76 who have a history of these infections. This Phase 3 randomized, double-blind, placebo-controlled trial compares U101 to a placebo to assess its ability to reduce UTI recurrence, improve quality of life, and monitor safety. The study involves women with defined criteria for rUTI history and a negative infection status before starting treatment. Participants will take one capsule of U101 or placebo orally three times a day for the first 8 weeks, then twice a day for the following 16 weeks during the 24-week main study. They will visit the study site every 4 weeks for checkups and tests. Afterward, participants may join an optional 24-week open-label extension OLE where those who had a UTI episode during the main study can receive U101 treatment again or enter long-term safety follow-up without treatment, with visits at Weeks 8 and 24. During the study, participants will report any suspected UTI symptoms for special visits and tests. Researchers will evaluate UTI recurrence, quality of life measures, safety labs, physical exams, and vital signs throughout the main and extension studies. The primary analysis will review the percentage of participants without UTI recurrence after 24 weeks, with ongoing safety monitoring extending 14 days post-treatment. Total participation may last up to 48 weeks including the extension or follow-up periods.
1-10 of 18
1